Literature DB >> 25716968

Acute anti-fibrillating and defibrillating potential of atorvastatin, melatonin, eicosapentaenoic acid and docosahexaenoic acid demonstrated in isolated heart model.

T Benova1, V Knezl, C Viczenczova, B S Bacova, J Radosinska, N Tribulova.   

Abstract

Cardioprotective compounds such as atorvastatin, melatonin, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) exhibit antiarrhythmic potential in clinical and/or experimental conditions but underlying mechanisms are poorly understood. We have previously shown that protection from ventricular fibrillation (VF) due to prolonged treatment with these compounds was linked with modulation of myocardial connexin-43, which is responsible for myocardial electrical coupling and synchronisation. To elucidate further the antiarrhythmic potential of atorvastatin, melatonin, EPA and DHA we aimed to explore their acute anti-fibrillating effects and defibrillating efficacy. Experiments were conducted on isolated perfused heart preparation of adult male and female hypertriglyceridemic (HTG) rats when using atorvastatin, EPA and DHA, while melatonin was examined in hearts of old male and female guinea pigs. VF inducibility was tested in hearts pre-treated for 10 min with atorvastatin, EPA or DHA (15 μmol) or melatonin (50 μmol) and compared with non-pre-treated hearts. Sustained VF was induced in all untreated HTG rat hearts. In contrast, its incidence was reduced to 30% and 60% by atorvastatin, 70% and 75% by EPA, 60% and 60% by DHA in male or female rat hearts respectively. Moreover, bolus (150 μmol) of EPA and DHA administered directly to the fibrillating heart restored sinus rhythm in 6 of 6 hearts and atorvastatin in 4 of 6 hearts. Threshold to induce sustained VF was 21.7 ± 3.8 mA in male and 38.3 ± 2.9 mA in female guinea pig hearts. However, sustained VF was not possible to induce even by the strongest (50 mA) stimulus in the heart pre-treated with melatonin regardless the sex. In conclusion, atorvastatin, melatonin, EPA and DHA exhibit clear cut acute anti-fibrillating efficacy. Findings challenge to investigate expression of connexin-43, especially its phosphorylated status associated with connexin channel function, in acute conditions.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25716968

Source DB:  PubMed          Journal:  J Physiol Pharmacol        ISSN: 0867-5910            Impact factor:   3.011


  11 in total

1.  Obesity-associated alterations in cardiac connexin-43 and PKC signaling are attenuated by melatonin and omega-3 fatty acids in female rats.

Authors:  Tamara Egan Benova; Csilla Viczenczova; Barbara Szeiffova Bacova; Vladimir Knezl; Victor Dosenko; Hana Rauchova; Michal Zeman; Russel J Reiter; Narcis Tribulova
Journal:  Mol Cell Biochem       Date:  2018-11-16       Impact factor: 3.396

2.  Melatonin increases the regularity of cardiac rhythmicity in the Drosophila heart in both wild-type and strains bearing pathogenic mutations.

Authors:  Tricia VanKirk; Evelyn Powers; Harold B Dowse
Journal:  J Comp Physiol B       Date:  2016-07-22       Impact factor: 2.200

3.  Altered thyroid status affects myocardial expression of connexin-43 and susceptibility of rat heart to malignant arrhythmias that can be partially normalized by red palm oil intake.

Authors:  Barbara Szeiffová Bačová; Csilla Vinczenzová; Jitka Žurmanová; Dita Kašparová; Vladimír Knezl; Tamara Egan Beňová; Stanislav Pavelka; Tomáš Soukup; Narcisa Tribulová
Journal:  Histochem Cell Biol       Date:  2016-09-06       Impact factor: 4.304

Review 4.  Omega-3 Index and Anti-Arrhythmic Potential of Omega-3 PUFAs.

Authors:  Narcis Tribulova; Barbara Szeiffova Bacova; Tamara Egan Benova; Vladimir Knezl; Miroslav Barancik; Jan Slezak
Journal:  Nutrients       Date:  2017-10-30       Impact factor: 5.717

5.  Monotherapy of experimental metabolic syndrome: II. Study of cardiovascular effects.

Authors:  Vladimír Knezl; Ružena Sotníková; Zuzana Brnoliaková; Tatiana Stankovičová; Viktor Bauer; Štefan Bezek
Journal:  Interdiscip Toxicol       Date:  2018-02-14

Review 6.  Melatonin to Rescue the Aged Heart: Antiarrhythmic and Antioxidant Benefits.

Authors:  Margarita Segovia-Roldan; Emiliano Raúl Diez; Esther Pueyo
Journal:  Oxid Med Cell Longev       Date:  2021-03-13       Impact factor: 6.543

7.  Melatonin Prevents Early but Not Delayed Ventricular Fibrillation in the Experimental Porcine Model of Acute Ischemia.

Authors:  Alena S Tsvetkova; Olesya G Bernikova; Natalya J Mikhaleva; Darya S Khramova; Alexey O Ovechkin; Marina M Demidova; Pyotr G Platonov; Jan E Azarov
Journal:  Int J Mol Sci       Date:  2020-12-30       Impact factor: 5.923

Review 8.  Mechanisms Underlying Antiarrhythmic Properties of Cardioprotective Agents Impacting Inflammation and Oxidative Stress.

Authors:  Katarina Andelova; Barbara Szeiffova Bacova; Matus Sykora; Peter Hlivak; Miroslav Barancik; Narcis Tribulova
Journal:  Int J Mol Sci       Date:  2022-01-26       Impact factor: 5.923

Review 9.  Anti-arrhythmic properties of non-antiarrhythmic medications.

Authors:  Emmanuel Ato Williams; Vincenzo Russo; Sergio Ceraso; Dhiraj Gupta; Richard Barrett-Jolley
Journal:  Pharmacol Res       Date:  2020-03-23       Impact factor: 7.658

Review 10.  Cardioprotective Melatonin: Translating from Proof-of-Concept Studies to Therapeutic Use.

Authors:  Ovidiu Constantin Baltatu; Sergio Senar; Luciana Aparecida Campos; José Cipolla-Neto
Journal:  Int J Mol Sci       Date:  2019-09-05       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.